Patents by Inventor Jin Yong Chung

Jin Yong Chung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11968312
    Abstract: Disclosed herein are an apparatus and method for processing vehicle data security based on a cloud.
    Type: Grant
    Filed: November 16, 2021
    Date of Patent: April 23, 2024
    Assignee: ELECTRONICS AND TELECOMMUNICATIONS RESEARCH INSTITUTE
    Inventors: Sang-Woo Lee, Dae-Won Kim, Jin-Yong Lee, Boo-Sun Jeon, Bo-Heung Chung, Hong-Il Ju, Joong-Yong Choi
  • Publication number: 20230218562
    Abstract: The present disclosure provides a compound represented by Formula (I) and a pharmaceutically acceptable salt which are effective as a dopamine reuptake inhibitor and a method of using the compound: wherein X is independently halo, alkyl, alkoxy or nitro; m is 0, 1, 2, 3 or 4; n is 1 or 2; R1 and R2 are independently H— or alkyl; R3 is H—, alkyl or aralkyl; and R4 is H— or aryl.
    Type: Application
    Filed: March 22, 2023
    Publication date: July 13, 2023
    Inventors: Young-Soon KANG, Jin-Yong CHUNG, Cheol-Young MAENG, Han-Ju YI, Ki-Ho LEE, Joon HEO, Eun-Hee CHAE, Yu-Jin SHIN
  • Publication number: 20220370461
    Abstract: The present invention relates to a use of imidazopyrimidine or imidazotriazine compounds of Chemical Formula 1, or pharmaceutically acceptable salts, solvates, or hydrates thereof, for preventing, alleviating or treating cognitive disorder or for improving enhancing cognitive function.
    Type: Application
    Filed: October 21, 2020
    Publication date: November 24, 2022
    Inventors: Chan Mi JOUNG, Jin Yong CHUNG
  • Patent number: 11231777
    Abstract: A method of controlling a device is provided. The method includes receiving eye movement information of a user. A gazed position within a display area of the device is identified based on the eye movement information of the user. A position of a cursor corresponding to the gazed position is corrected based on the eye movement information. A control command corresponding to an area within the display area of the device is generated, based on the gazed position and the eye movement information. An operation of the device is controlled based on the control command.
    Type: Grant
    Filed: May 11, 2020
    Date of Patent: January 25, 2022
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Jun-seok Lee, Kyung-hwa Yu, Sang-won Leigh, Jin-yong Chung, Sung-goo Cho
  • Publication number: 20210300933
    Abstract: The present disclosure provides a compound of Chemical Formula (1) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same: wherein X, Z, R1 and R2 are as defined in the specification. The compound of Chemical Formula (1) or pharmaceutically acceptable salt thereof acts as a positive allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5), thereby being useful in the prevention or treatment of disorder mediated by glutamate dysfunction and mGluR5.
    Type: Application
    Filed: June 1, 2021
    Publication date: September 30, 2021
    Inventors: Chun Eung PARK, Young Koo JANG, Yong Je SHIN, Ji Yeon KIM, Seung Mo HAM, Yong Gil KIM, Hye Kyung MIN, Soo Bong CHA, Hyo Jun JUNG, Ju Young LEE, Seung Nam HAN, Jin Yong CHUNG, Eun Ju CHOI, Chan Mi JOUNG, Jong Sil PARK, Ji Won LEE, Nahm Ryune CHO, Eun Ju RYU, Cheol Young MAENG
  • Patent number: 11046702
    Abstract: The present disclosure provides a compound of Chemical Formula (1) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same: wherein X, Z, R1 and R2 are as defined in the specification. The compound of Chemical Formula (1) or pharmaceutically acceptable salt thereof acts as a positive allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5), thereby being useful in the prevention or treatment of disorder mediated by glutamate dysfunction and mGluR5.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: June 29, 2021
    Assignee: SK BIOPHARMACEUTICALS CO., LTD.
    Inventors: Chun Eung Park, Young Koo Jang, Yong Je Shin, Ji Yeon Kim, Seung Mo Ham, Yong Gil Kim, Hye Kyung Min, Soo Bong Cha, Hyo Jun Jung, Ju Young Lee, Seung Nam Han, Jin Yong Chung, Eun Ju Choi, Chan Mi Joung, Jong Sil Park, Ji Won Lee, Nahm Ryune Cho, Eun Ju Ryu, Cheol Young Maeng
  • Publication number: 20210113514
    Abstract: The present disclosure provides a compound represented by Formula (I) and a pharmaceutically acceptable salt which are effective as a dopamine reuptake inhibitor and a method of using the compound: wherein X is independently halo, alkyl, alkoxy or nitro; m is 0, 1, 2, 3 or 4; n is 1 or 2; R1 and R2 are independently H— or alkyl; R3 is H—, alkyl or aralkyl; and R4 is H— or aryl.
    Type: Application
    Filed: December 29, 2020
    Publication date: April 22, 2021
    Inventors: Young-Soon KANG, Jin-Yong CHUNG, Cheol-Young MAENG, Han-Ju YI, Ki-Ho LEE, Joon HEO, Eun-Hee CHAE, Yu-Jin SHIN
  • Patent number: 10888542
    Abstract: The present disclosure provides a compound represented by Formula (I) and a pharmaceutically acceptable salt which are effective as a dopamine reuptake inhibitor and a method of using the compound: wherein X is independently halo, alkyl, alkoxy or nitro; m is 0, 1, 2, 3 or 4; n is 1 or 2; R1 and R2 are independently H— or alkyl; R3 is H—, alkyl or aralkyl; and R4 is H— or aryl.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: January 12, 2021
    Assignee: SK BIOPHARMACEUTICALS CO., LTD.
    Inventors: Young-Soon Kang, Jin-Yong Chung, Cheol-Young Maeng, Han-Ju Yi, Ki-Ho Lee, Joon Heo, Eun-Hee Chae, Yu-Jin Shin
  • Publication number: 20200277298
    Abstract: The present disclosure provides a compound of Chemical Formula (1) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same: wherein X, Z, R1 and R2 are as defined in the specification. The compound of Chemical Formula (1) or pharmaceutically acceptable salt thereof acts as a positive allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5), thereby being useful in the prevention or treatment of disorder mediated by glutamate dysfunction and mGluR5.
    Type: Application
    Filed: April 17, 2020
    Publication date: September 3, 2020
    Inventors: Chun Eung PARK, Young Koo JANG, Yong Je SHIN, Ji Yeon KIM, Seung Mo HAM, Yong Gil KIM, Hye Kyung MIN, Soo Bong CHA, Hyo Jun JUNG, Ju Young LEE, Seung Nam HAN, Jin Yong CHUNG, Eun Ju CHOI, Chan Mi JOUNG, Jong Sil PARK, Ji Won LEE, Nahm Ryune CHO, Eun Ju RYU, Cheol Young MAENG
  • Publication number: 20200272234
    Abstract: A method of controlling a device is provided. The method includes receiving eye movement information of a user. A gazed position within a display area of the device is identified based on the eye movement information of the user. A position of a cursor corresponding to the gazed position is corrected based on the eye movement information. A control command corresponding to an area within the display area of the device is generated, based on the gazed position and the eye movement information. An operation of the device is controlled based on the control command.
    Type: Application
    Filed: May 11, 2020
    Publication date: August 27, 2020
    Applicant: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Jun-seok LEE, Kyung-hwa YU, Sang-won LEIGH, Jin-yong CHUNG, Sung-goo CHO
  • Publication number: 20200081531
    Abstract: A method of controlling a device is provided. The method includes receiving eye movement information of a user. A gazed position within a display area of the device is identified based on the eye movement information of the user. A position of a cursor corresponding to the gazed position is corrected based on the eye movement information. A control command corresponding to an area within the display area of the device is generated, based on the gazed position and the eye movement information. An operation of the device is controlled based on the control command.
    Type: Application
    Filed: November 13, 2019
    Publication date: March 12, 2020
    Applicant: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Jun-seok LEE, Kyung-hwa YU, Sang-won LEIGH, Jin-yong CHUNG, Sung-goo CHO
  • Publication number: 20200046674
    Abstract: The present disclosure provides a compound represented by Formula (I) and a pharmaceutically acceptable salt which are effective as a dopamine reuptake inhibitor and a method of using the compound: wherein X is independently halo, alkyl, alkoxy or nitro; m is 0, 1, 2, 3 or 4; n is 1 or 2; R1 and R2 are independently H— or alkyl; R3 is H—, alkyl or aralkyl; and R4 is H— or aryl.
    Type: Application
    Filed: October 16, 2019
    Publication date: February 13, 2020
    Inventors: Young-Soon KANG, Jin-Yong CHUNG, Cheol-Young MAENG, Han-Ju YI, Ki-Ho LEE, Joon HEO, Eun-Hee CHAE, Yu-Jin SHIN
  • Patent number: 10485781
    Abstract: The present disclosure provides a compound represented by Formula (I) and a pharmaceutically acceptable salt which are effective as a dopamine reuptake inhibitor and a method of using the compound: wherein X is independently halo, alkyl, alkoxy or nitro; m is 0, 1, 2, 3 or 4; n is 1 or 2; R1 and R2 are independently H— or alkyl; R3 is H—, alkyl or aralkyl; and R4 is H— or aryl.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: November 26, 2019
    Assignee: SK BIOPHARMACEUTICALS CO., LTD.
    Inventors: Young-Soon Kang, Jin-Yong Chung, Cheol-Young Maeng, Han-Ju Yi, Ki-Ho Lee, Joon Heo, Eun-Hee Chae, Yu-Jin Shin
  • Patent number: 10481685
    Abstract: A method of controlling an operation of a display device using eye movements and a device for performing the method are provided. The method includes receiving eye movement information of a user; receiving blinking information of the user; generating a control command corresponding to the eye movement information and the blinking information; and controlling an operation of the display device based on the generated control command.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: November 19, 2019
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Jun-seok Lee, Kyung-hwa Yu, Sang-won Leigh, Jin-yong Chung, Sung-goo Cho
  • Publication number: 20190247356
    Abstract: The present disclosure provides a compound represented by Formula (I) and a pharmaceutically acceptable salt which are effective as a dopamine reuptake inhibitor and a method of using the compound: wherein X is independently halo, alkyl, alkoxy or nitro; m is 0, 1, 2, 3 or 4; n is 1 or 2; R1 and R2 are independently H— or alkyl; R3 is H—, alkyl or aralkyl; and R4 is H— or aryl.
    Type: Application
    Filed: April 26, 2019
    Publication date: August 15, 2019
    Inventors: Young-Soon KANG, Jin-Yong CHUNG, Cheol-Young MAENG, Han-Ju YI, Ki-Ho LEE, Joon HEO, Eun-Hee CHAE, Yu-Jin SHIN
  • Patent number: 10314808
    Abstract: The present disclosure provides a compound represented by Formula (I) and a pharmaceutically acceptable salt which are effective as a dopamine reuptake inhibitor and a method of using the compound: wherein X is independently halo, alkyl, alkoxy or nitro; m is 0, 1, 2, 3 or 4; n is 1 or 2; R1 and R2 are independently H— or alkyl; R3 is H—, alkyl or aralkyl; and R4 is H— or aryl.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: June 11, 2019
    Assignee: SK BIOPHARMACEUTICALS CO., LTD.
    Inventors: Young-Soon Kang, Jin-Yong Chung, Cheol-Young Maeng, Han-Ju Yi, Ki-Ho Lee, Joon Heo, Eun-Hee Chae, Yu-Jin Shin
  • Publication number: 20190031669
    Abstract: The present disclosure provides a compound of Chemical Formula (1) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same: wherein X, Z, R1 and R2 are as defined in the specification. The compound of Chemical Formula (1) or pharmaceutically acceptable salt thereof acts as a positive allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5), thereby being useful in the prevention or treatment of disorder mediated by glutamate dysfunction and mGluR5.
    Type: Application
    Filed: September 28, 2018
    Publication date: January 31, 2019
    Inventors: Chun Eung PARK, Young Koo JANG, Yong Je SHIN, Ji Yeon KIM, Seung Mo HAM, Yong Gil KIM, Hye Kyung MIN, Soo Bong CHA, Hyo Jun JUNG, Ju Young LEE, Seung Nam HAN, Jin Yong CHUNG, Eun Ju CHOI, Chan Mi JOUNG, Jong Sil PARK, Ji Won LEE, Nahm Ryune CHO, Eun Ju RYU, Cheol Young MAENG
  • Patent number: 10100057
    Abstract: The present disclosure provides a compound of Chemical Formula (1) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same: wherein X, Z, R1 and R2 are as defined in the specification. The compound of Chemical Formula (1) or pharmaceutically acceptable salt thereof acts as a positive allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5), thereby being useful in the prevention or treatment of disorder mediated by glutamate dysfunction and mGluR5.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: October 16, 2018
    Assignee: SK BIOPHARMACEUTICALS CO., LTD.
    Inventors: Chun Eung Park, Young Koo Jang, Yong Je Shin, Ji Yeon Kim, Seung Mo Ham, Yong Gil Kim, Hye Kyung Min, Soo Bong Cha, Hyo Jun Jung, Ju Young Lee, Seung Nam Han, Jin Yong Chung, Eun Ju Choi, Chan Mi Joung, Jong Sil Park, Ji Won Lee, Nahm Ryune Cho, Eun Ju Ryu, Cheol Young Maeng
  • Publication number: 20180129283
    Abstract: A method of controlling an operation of a display device using eye movements and a device for performing the method are provided. The method includes receiving eye movement information of a user; receiving blinking information of the user; generating a control command corresponding to the eye movement information and the blinking information; and controlling an operation of the display device based on the generated control command.
    Type: Application
    Filed: January 8, 2018
    Publication date: May 10, 2018
    Applicant: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Jun-seok LEE, Kyung-hwa YU, Sang-won LEIGH, Jin-yong CHUNG, Sung-goo CHO
  • Publication number: 20180085337
    Abstract: The present disclosure provides a compound represented by Formula (I) and a pharmaceutically acceptable salt which are effective as a dopamine reuptake inhibitor and a method of using the compound: wherein X is independently halo, alkyl, alkoxy or nitro; m is 0, 1, 2, 3 or 4; n is 1 or 2; R1 and R2 are independently H— or alkyl; R3 is H—, alkyl or aralkyl; and R4 is H— or aryl.
    Type: Application
    Filed: November 7, 2017
    Publication date: March 29, 2018
    Inventors: Young-Soon KANG, Jin-Yong CHUNG, Cheol-Young MAENG, Han-Ju YI, Ki-Ho LEE, Joon HEO, Eun-Hee CHAE, Yu-Jin SHIN